Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis

[1]  B. Strober,et al.  Hidradenitis suppurativa: Current and emerging treatments. , 2020 .

[2]  J. Dudley,et al.  Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  M. Bendall,et al.  Transcriptome patterns in hidradenitis suppurativa: support for the role of antimicrobial peptides and interferon pathways in disease pathogenesis , 2019, Clinical and experimental dermatology.

[4]  M. Suárez-Fariñas,et al.  Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature , 2018, PloS one.

[5]  B. Moran,et al.  Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. , 2017, The Journal of investigative dermatology.

[6]  J. Szepietowski,et al.  Increased interleukin (IL)‐17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti‐IL‐17 agents , 2017, Journal of the American Academy of Dermatology.

[7]  A. Gottlieb,et al.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. , 2016, The New England journal of medicine.

[8]  T. Gambichler,et al.  Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). , 2015, Journal of the American Academy of Dermatology.

[9]  K. Radcliffe,et al.  Hidradenitis suppurativa. , 1991, Genitourinary medicine.

[10]  A. Kimball,et al.  Hidradenitis suppurativa , 1987, Nature Reviews Disease Primers.

[11]  M. Sundaram,et al.  Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. , 2016, Dermatology online journal.